The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the pertussis vaccine market in recent years?
Rising childbirth rates are driving the growth of the pertussis vaccine market going forward. Childbirth is the term for the act of giving birth to a child. It is the culmination of pregnancy, during which the fetus develops in the mother’s uterus and marks the beginning of a new life outside the womb. The pertussis vaccine is primarily used for children because it helps protect them from whooping cough and other severe and potentially deadly diseases. For instance, in January 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based national public health organization, the United States witnessed a 1% increase in registered births, totaling 3,664,292, compared to the previous year. Therefore, the rising childbirth rates are driving the growth of the pertussis vaccine market.
Pertussis Vaccine Market Driver: Increase In Number Of Geriatric Population To Drive The Growth Of Pertussis Vaccine Market
The increasing number of geriatric populations is expected to propel the growth of the pertussis vaccine market. The geriatric population refers to the demographic group consisting of individuals who are elderly or in their later stages of life, typically aged 65 and older. The increasing number of geriatric populations is a major factor in the pertussis vaccine market. As more people live longer, there is an increased demand for the pertussis vaccine to protect older adults from this serious disease. For instance, in October 2022, according to the World Health Organization, a Switzerland-based intergovernmental health organization, the global population of individuals aged 60 years and above is projected to double by 2050, reaching 2.1 billion, while the number of people aged 80 years or older is anticipated to triple from 2020 to 2050, reaching 426 million. Therefore, the increasing geriatric population is driving the growth of the pertussis vaccine market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp
What is the projected market size of the pertussis vaccine industry, and how is it expected to grow?
The pertussis vaccine market size has grown steadily in recent years. It will grow from $5.5 billion in 2024 to $5.72 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to disease prevalence, immunization programs, pediatric vaccination, regulatory approvals.
The pertussis vaccine market size is expected to see steady growth in the next few years. It will grow to $6.62 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to booster vaccination, maternal immunization, immunization for healthcare workers, global health initiatives. Major trends in the forecast period include personalized immunization schedules, combination vaccines, vaccine equity initiatives, digital health for immunization.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13023&type=smp
Who are the key players driving competition in the pertussis vaccine market?
Major companies operating in the pertussis vaccine market are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, BioNTech SE, Moderna Inc., Sinovac Biotech Ltd., CSL Limited, Astellas Pharma US Inc., Sanofi Pasteur SA, Mitsubishi Tanabe Pharma America Inc., PT Kalbe Farma Tbk, CSL Seqirus, Walvax Biotechnology Co.Ltd., Biological E. Limited, Serum Institute of India, Bavarian Nordic AS, PT Bio Farma, Bharat Biotech International Limited, Takeda Pharmaceutical Company, Panacea Biotec Limited, Beijing Minhai Biotechnology Co. Ltd., Protein Sciences Corporation, Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Gennova Biopharmaceuticals Ltd., Chiron Corporation.
What key trends are expected to drive the personalized learning market during the forecast period?
Major companies operating in the pertussis vaccine market are developing innovative drugs and getting approvals to sustain their position in the market. For instance, in October 2022, GSK plc., a UK-based pharmaceutical and biotechnology company, announced that BOOSTRIX was approved by the U.S. Food and Drug Administration (FDA). BOOSTRIX is a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) vaccine. It is used during pregnancy to prevent pertussis (whooping cough) in newborn infants. It is injected once into the upper arm muscle. Boostrix is safe and effective for pregnant women and their babies. Additionally, it effectively prevents pertussis, including severe cases of the disease.
Which key geographies are driving the growth of the pertussis vaccine market?
North America was the largest region in the pertussis vaccine market in 2024. The regions covered in pertussis vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report
What are the key segments driving growth in the pertussis vaccine market?
The pertussis vaccine market covered in this report is segmented –
1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine
2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine
3) By Application: Children, Adults, Infants
4) By End-User: Vaccination Centers, Hospitals, Clinics
Subsegments:
1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP
2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13023
How is the pertussis vaccine market defined, and what are its core characteristics?
The pertussis vaccine refers to a vaccine that protects against whooping cough (pertussis), which is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It is designed to stimulate the immune system to produce protective antibodies against the pertussis bacterium, thus reducing the risk of infection and its associated symptoms.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
